{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T12:40:18Z","timestamp":1790944818363,"version":"4.1.0"},"reference-count":113,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2007,12,11]],"date-time":"2007-12-11T00:00:00Z","timestamp":1197331200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Osteoporos Int"],"published-print":{"date-parts":[[2008,4]]},"DOI":"10.1007\/s00198-007-0490-1","type":"journal-article","created":{"date-parts":[[2007,12,10]],"date-time":"2007-12-10T11:00:25Z","timestamp":1197284425000},"page":"479-491","source":"Crossref","is-referenced-by-count":192,"title":["Salmon calcitonin: a review of current and future therapeutic indications"],"prefix":"10.1007","volume":"19","author":[{"suffix":"III","given":"C. H.","family":"Chesnut","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Azria","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Silverman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Engelhardt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Olson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Mindeholm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2007,12,11]]},"reference":[{"key":"490_CR1","doi-asserted-by":"crossref","first-page":"2038","DOI":"10.1126\/science.134.3495.2038","volume":"134","author":"DH Copp","year":"1961","unstructured":"Copp DH, Cameron EC (1961) Demonstration of a hypocalcemic factor (calcitonin) in commercial parathyroid extract. Science 134:2038","journal-title":"Science"},{"key":"490_CR2","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1007\/BF00301940","volume":"57","author":"M Azria","year":"1995","unstructured":"Azria M, Copp D, Zanelli J (1995) 25\u00a0years of salmon calcitonin: from synthesis to therapeutic use. Calcif Tissue Int 57:405\u2013408","journal-title":"Calcif Tissue Int"},{"issue":"Suppl 2","key":"490_CR3","first-page":"S37","volume":"18","author":"JP Woodrow","year":"2003","unstructured":"Woodrow JP, Noseworthy CS, Fudge NJ, Hoff AO, Gagel RF, Kovacs CS (2003) Calcitonin\/calcitonin gene-related peptide protect the maternal skeleton from excessive resorption during lactation [abstract]. J Bone Miner Res 18(Suppl 2):S37","journal-title":"J Bone Miner Res"},{"key":"490_CR4","first-page":"1062","volume":"23","author":"A Hoff","year":"1998","unstructured":"Hoff A, Thomas M, Cote G (1998) Generation of a calcitonin knockout mouse model [abstract]. Bone 23:1062","journal-title":"Bone"},{"key":"490_CR5","doi-asserted-by":"crossref","first-page":"1849","DOI":"10.1172\/JCI200214218","volume":"110","author":"AO Hoff","year":"2002","unstructured":"Hoff AO, Catala-Lehnen P, Thomas PM, Priemel M, Rueger JM, Nasonkin I, Bradley A, Hughes MR, Ordonez N, Cote GJ, Amling M, Gagel RF (2002) Increased bone mass is an unexpected phenotype associated with deletion of the calcitonin gene. J Clin Invest 110:1849\u20131857","journal-title":"J Clin Invest"},{"key":"490_CR6","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1385\/ENDO:21:3:201","volume":"21","author":"PF Hirsch","year":"2003","unstructured":"Hirsch PF, Baruch H (2003) Is calcitonin an important physiological substance? Endocrine 21:201\u2013208","journal-title":"Endocrine"},{"key":"490_CR7","first-page":"118","volume":"46","author":"G Thamsborg","year":"1999","unstructured":"Thamsborg G (1999) Effect of nasal salmon calcitonin on calcium and bone metabolism. Dan Med Bull 46:118\u2013126","journal-title":"Dan Med Bull"},{"key":"490_CR8","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1007\/BF02555225","volume":"41","author":"T Buclin","year":"1987","unstructured":"Buclin T, Randin J, Jacquet A, Azria M, Attinger M, Gomez F, Burckhardt P (1987) The effect of rectal and nasal administration of salmon calcitonin in normal subjects. Calcif Tissue Int 41:252\u2013258","journal-title":"Calcif Tissue Int"},{"issue":"Suppl","key":"490_CR9","doi-asserted-by":"crossref","first-page":"S26","DOI":"10.1007\/BF02553290","volume":"46","author":"L Wisneski","year":"1990","unstructured":"Wisneski L (1990) Salmon calcitonin in the acute management of hypercalcemia. Calcif Tissue Int 46(Suppl):S26\u2013S30","journal-title":"Calcif Tissue Int"},{"key":"490_CR10","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1016\/B978-012098652-1.50184-0","volume-title":"Principles of bone biology","author":"M Zaidi","year":"2002","unstructured":"Zaidi M, Inzerillo A, Troen B et al (2002) Molecular and clinical pharmacology of calcitonin. In: Bilezikian J, Raisz L, Rodan G (eds) Principles of bone biology. Academic press, San Diego, pp 1423\u20131440"},{"key":"490_CR11","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s00223-001-1135-6","volume":"74","author":"SH Ralston","year":"2004","unstructured":"Ralston SH, Coleman R, Fraser WD, Gallagher SJ, Hosking DJ, Iqbal JS, McCloskey E, Sampson D (2004) Medical management of hypercalcemia. Calcif Tissue Int 74:1\u201311","journal-title":"Calcif Tissue Int"},{"key":"490_CR12","first-page":"359","volume":"211","author":"D Hoskin","year":"1984","unstructured":"Hoskin D, Gilson D (1984) Comparison of the renal and skeletal actions of calcitonin in the treatment of severe hypercalcemia of malignancy. Quart J Med 211:359\u2013368","journal-title":"Quart J Med"},{"key":"490_CR13","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1172\/JCI112584","volume":"78","author":"G Nicholson","year":"1986","unstructured":"Nicholson G, Moseley J, Sexton P, Mendelsohn F, Martin T (1986) Abundant calcitonin receptors in isolate rat osteoclasts, biochemical, and autoradiographic characterization. J Clin Invest 78:355\u2013360","journal-title":"J Clin Invest"},{"key":"490_CR14","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1083\/jcb.60.2.346","volume":"60","author":"N Holtrop","year":"1974","unstructured":"Holtrop N, Raisz L, Simmons H (1974) The effects of parathyroid hormone, colchicines and calcitonin on the ultrastructure and the activity of osteoclasts in organ culture. J Cell Biol 60:346\u2013355","journal-title":"J Cell Biol"},{"key":"490_CR15","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1002\/jbmr.5650060610","volume":"6","author":"S Yumita","year":"1991","unstructured":"Yumita S, Nicholson G, Rowe D, Kent G, Martin T (1991) Biphasic effect of calcitonin on tartrate-resistant acid phosphatase activity in isolated rat osteoclasts. J Bone Miner Res 6:591\u2013597","journal-title":"J Bone Miner Res"},{"key":"490_CR16","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1016\/S8756-3282(02)00688-9","volume":"30","author":"M Zaidi","year":"2002","unstructured":"Zaidi M, Inzerillo A, Moonga B, Bevis P, Huang C (2002) Forty years of calcitonin-where are we now? A tribute to the work of Iain Macintyre, FRS. Bone 30:655\u2013663","journal-title":"Bone"},{"key":"490_CR17","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1210\/jcem-57-4-819","volume":"57","author":"T Chambers","year":"1983","unstructured":"Chambers T, Moore A (1983) The sensitivity of isolated osteoclasts to morphological transformation by calcitonin. J Clin Endo Metab 57:819\u2013824","journal-title":"J Clin Endo Metab"},{"key":"490_CR18","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1002\/path.1711360104","volume":"136","author":"T Chambers","year":"1982","unstructured":"Chambers T, Magnus C (1982) Calcitonin alters behaviour of isolated osteoclasts. J Pathol 136:27\u201339","journal-title":"J Pathol"},{"key":"490_CR19","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1016\/j.addr.2004.12.018","volume":"57","author":"K Vaananen","year":"2005","unstructured":"Vaananen K (2005) Mechanism of osteoclast mediated bone resorption-rationale for the design of new therapeutics. Adv Drug Deliv Rev 57:959\u2013971","journal-title":"Adv Drug Deliv Rev"},{"key":"490_CR20","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/0303-7207(96)03870-1","volume":"122","author":"KS Selander","year":"1996","unstructured":"Selander KS, Harkonen PL, Valve E, Monkkonen J, Hannuniemi R, Vaananen HK (1996) Calcitonin promotes osteoclast survival in vitro. Mol Cell Endocrinol 122:119\u2013129","journal-title":"Mol Cell Endocrinol"},{"key":"490_CR21","doi-asserted-by":"publisher","first-page":"1363","DOI":"10.1172\/JCI6800","volume":"104","author":"L Plotkin","year":"1999","unstructured":"Plotkin L, Weinstein R, Parfitt A, Robertson P, Manolagas S, Bellido T (1999) Prevention of osteocyte and osteoblast apoptosis by bisphosphonates and calcitonin. J Clin Invest 104:1363\u20131374","journal-title":"J Clin Invest"},{"key":"490_CR22","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1210\/endo-123-1-159","volume":"123","author":"JR Farley","year":"1988","unstructured":"Farley JR, Tarbaux NM, Hall SL, Linkhart TA, Baylink DJ (1988) The anti-bone-resorptive agent calcitonin also acts in vitro to directly increase bone formation and bone cell proliferation. Endocrinology 123:159\u2013167","journal-title":"Endocrinology"},{"key":"490_CR23","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1007\/BF00310194","volume":"52","author":"S Wallach","year":"1993","unstructured":"Wallach S, Farley JR, Baylink DJ, Brenner-Gati L (1993) Effects of calcitonin on bone quality and osteoblastic function. Calcif Tissue Int 52:335\u2013339","journal-title":"Calcif Tissue Int"},{"key":"490_CR24","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1248\/bpb.23.946","volume":"23","author":"H Furuichi","year":"2000","unstructured":"Furuichi H, Fukuyama R, Izumo N, Fujita T, Kohno T, Nakamuta H, Koida M (2000) Bone-anabolic effect of salmon calcitonin on glucocorticoid-induced osteopenia in rats. Biol Pharm Bull 23:946\u2013951","journal-title":"Biol Pharm Bull"},{"key":"490_CR25","first-page":"1162","volume":"(Suppl.)","author":"A Voss","year":"2005","unstructured":"Voss A, Liese S, Priemel M, Catala-Lehnen P, Schilling AF, Mueldner C, Haberland M, Rueger JM, Emeson RB, Gagel RF, Schinke T, Amling M (2005) Uncovering the physiologic function of calcitonin using genetically modified mouse models [abstract]. J Bone Min Res (Suppl.):1162","journal-title":"J Bone Min Res"},{"key":"490_CR26","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1172\/JCI117634","volume":"95","author":"S Takahashi","year":"1995","unstructured":"Takahashi S, Goldring S, Katz M, Hilsenbeck S, Williams R, Roodman GD (1995) Downregulation of calcitonin receptor mRNA expression by calcitonin during human osteoclast-like cell differentiation. J Clin Invest 95:167\u2013171","journal-title":"J Clin Invest"},{"key":"490_CR27","doi-asserted-by":"crossref","first-page":"2331","DOI":"10.1172\/JCI107044","volume":"51","author":"FR Singer","year":"1972","unstructured":"Singer FR, Aldred JP, Neer RM, Krane SM, Potts JT Jr, Bloch KJ (1972) An evaluation of antibodies and clinical resistance to salmon calcitonin. J Clin Invest 51:2331\u20132338","journal-title":"J Clin Invest"},{"key":"490_CR28","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/S0002-9343(00)00490-3","volume":"109","author":"CH Chesnut 3rd","year":"2000","unstructured":"Chesnut CH 3rd, Silverman S, Andriano K, Genant H, Gimona A, Harris S, Kiel D, LeBoff M, Maricic M, Miller P, Moniz C, Peacock M, Richardson P, Watts N, Baylink D (2000) A randomized trial of nasal spray salmon calcitonin in postmenopausal women with established osteoporosis: the prevent recurrence of osteoporotic fractures study. PROOF Study Group. Am J Med. 109:267\u2013276","journal-title":"Am J Med"},{"key":"490_CR29","doi-asserted-by":"crossref","first-page":"5064","DOI":"10.1073\/pnas.82.15.5064","volume":"83","author":"S Kittur","year":"1985","unstructured":"Kittur S, Hoppener J, Anatonarakis S, Daniels J, Meyers D, Maestry N, Jaansen M, Korneluk R, Nelkin B, Kazaziam H (1985) Linkage map of the short arm of human chromosome 11: location of the genes for catalase, calcitonin, and insulin-like growth factor II. Proc Natl Acad Sci 83:5064\u20135067","journal-title":"Proc Natl Acad Sci"},{"key":"490_CR30","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1007\/s002230001215","volume":"68","author":"M Nakamura","year":"2001","unstructured":"Nakamura M, Morimoto S, Zhang Z, Utusnomiya H, Inagami T, Ogihara T, Kakudo K (2001) Calcitonin receptor gene polymorphism in Japanese women; correlation with body mass and bone density. Calcif Tissue Int 68:211\u2013215","journal-title":"Calcif Tissue Int"},{"key":"490_CR31","first-page":"2225","volume":"29","author":"L Masi","year":"2002","unstructured":"Masi L, Cimaz R, Simonini G, Bindi G, Stagi S, Gozzini A, Malentacchi C, Brandi ML, Falcini F (2002) Association of low bone mass with vitamin D receptor gene and calcitonin receptor gene polymorphisms in juvenile idiopathic arthritis. J Rheumatol 29:2225\u20132231","journal-title":"J Rheumatol"},{"key":"490_CR32","doi-asserted-by":"crossref","first-page":"2129","DOI":"10.1093\/hmg\/7.13.2129","volume":"7","author":"J Taboulet","year":"1998","unstructured":"Taboulet J, Frenkian M, Frendo JL, Feingold N, Jullienne A, de Vernejoul MC (1998) Calcitonin receptor polymorphism is associated with a decreased fracture risk in post-menopausal women. Hum Mol Genet 7:2129\u20132133","journal-title":"Hum Mol Genet"},{"key":"490_CR33","unstructured":"Emisphere Technologies, Inc. is located in Tarrytown, NY and can be found at \n                    http:\/\/www.emisphere.com"},{"key":"490_CR34","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/0169-6009(92)90883-F","volume":"16","author":"H Rico","year":"1992","unstructured":"Rico H, Hernandez ER, Revilla M, Gomez-Castresana F (1992) Salmon calcitonin reduces vertebral fracture rate in postmenopausal crush fracture syndrome. Bone Miner 16:131\u2013138","journal-title":"Bone Miner"},{"key":"490_CR35","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1007\/BF02556587","volume":"38","author":"GF Mazzuoli","year":"1986","unstructured":"Mazzuoli GF, Passeri M, Gennari C, Minisola S, Antonelli R, Valtorta C, Palummeri E, Cervellin GF, Gonnelli S, Francini G (1986) Effects of salmon calcitonin in postmenopausal osteoporosis: a controlled double-blind clinical study. Calcif Tissue Int 38:3\u20138","journal-title":"Calcif Tissue Int"},{"key":"490_CR36","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/0028-2243(92)90214-J","volume":"47","author":"M Meschia","year":"1992","unstructured":"Meschia M, Brincat M, Barbacini P, Maini MC, Marri R, Crosignani PG (1992) Effect of hormone replacement therapy and calcitonin on bone mass in postmenopausal women. Eur J Obstet Gynecol Reprod Biol 47:53\u201357","journal-title":"Eur J Obstet Gynecol Reprod Biol"},{"key":"490_CR37","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1136\/bmj.305.6862.1124","volume":"305","author":"JA Kanis","year":"1992","unstructured":"Kanis JA, Johnell O, Gullberg B, Allander E, Dilsen G, Gennari C, Lopes Vaz AA, Lyritis GP, Mazzuoli G, Miravet L et al (1992) Evidence for efficacy of drugs affecting bone metabolism in preventing hip fracture. BMJ 305:1124\u20131128","journal-title":"BMJ"},{"key":"490_CR38","doi-asserted-by":"crossref","first-page":"1548","DOI":"10.1359\/JBMR.050411","volume":"20","author":"CH Chesnut 3rd","year":"2005","unstructured":"Chesnut CH 3rd, Majumdar S, Newitt DC, Shields A, Van Pelt J, Laschansky E, Azria M, Kriegman A, Olson M, Eriksen EF, Mindeholm L (2005) Effects of Salmon calcitonin on trabecular microarchitecture as determined by magnetic resonance imaging: Results From the QUEST study. J Bone Miner Res 20:1548\u20131561","journal-title":"J Bone Miner Res"},{"key":"490_CR39","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/S0009-8981(01)00731-8","volume":"316","author":"V Zikan","year":"2002","unstructured":"Zikan V, Stepan J (2002) Plasma type 1 collagen cross-linked C-telopeptide: a sensitive marker of acute effects of salmon calcitonin on bone resorption. Clin Chim Acta 316:63\u201369","journal-title":"Clin Chim Acta"},{"key":"490_CR40","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1007\/s00223-004-0036-x","volume":"75","author":"AK Srivastava","year":"2004","unstructured":"Srivastava AK, Libanati C, Hohmann O, Kriegman A, Baylink DJ (2004) Acute effects of calcitonin nasal spray on serum C-telopeptide of type 1 collagen (CTx) levels in elderly osteopenic women with increased bone turnover. Calcif Tissue Int 75:477\u2013481","journal-title":"Calcif Tissue Int"},{"key":"490_CR41","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0002-9343(90)90089-V","volume":"89","author":"K Overgaard","year":"1990","unstructured":"Overgaard K, Hansen MA, Nielson VA, Riis BJ, Christiansen C (1990) Discontinuous calcitonin treatment of established osteoporosis-effects of withdrawal of treatment. Am J Med 89:1\u20136","journal-title":"Am J Med"},{"key":"490_CR42","doi-asserted-by":"crossref","first-page":"1268","DOI":"10.1172\/JCI113725","volume":"82","author":"R Civitelli","year":"1988","unstructured":"Civitelli R, Gonnelli S, Zacchei F, Bigazzi S, Vattimo A, Avioli LV, Gennari C (1988) Bone turnover in postmenopausal osteoporosis. Effect of calcitonin treatment. J Clin Invest 82:1268\u20131274","journal-title":"J Clin Invest"},{"key":"490_CR43","unstructured":"Chesnut CH 3rd (2005) Personal communication"},{"key":"490_CR44","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1111\/j.1365-2265.1989.tb00443.x","volume":"30","author":"K Overgaard","year":"1989","unstructured":"Overgaard K, Riis BJ, Christiansen C, Podenphant J, Johansen JS (1989) Nasal calcitonin for treatment of established osteoporosis. Clin Endocrinol 30:435\u2013442","journal-title":"Clin Endocrinol"},{"key":"490_CR45","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1136\/bmj.305.6853.556","volume":"305","author":"K Overgaard","year":"1992","unstructured":"Overgaard K, Hansen MA, Jensen SB, Christiansen C (1992) Effect of salcatonin given intranasally on bone mass and fracture rates in established osteoporosis: a dose-response study. BMJ 305:556\u2013561","journal-title":"BMJ"},{"key":"490_CR46","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1136\/bmj.299.6697.477","volume":"299","author":"K Overgaard","year":"1989","unstructured":"Overgaard K, Riis BJ, Christiansen C, Hansen MA (1989) Effect of salcatonin given intranasally on early postmenopausal bone loss. BMJ 299:477\u2013479","journal-title":"BMJ"},{"key":"490_CR47","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1002\/jbmr.5650090110","volume":"9","author":"JY Reginster","year":"1994","unstructured":"Reginster JY, Denis D, Deroisy R, Lecart MP, De Longueville M, Zegels B, Sarlet N, Noirfalisse P, Franchimont P (1994) Long-term (3\u00a0years) prevention of trabecular postmenopausal bone loss with low-dose intermittent nasal salmon calcitonin. J Bone Miner Res 9:69\u201373","journal-title":"J Bone Miner Res"},{"key":"490_CR48","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1007\/s11926-005-0007-x","volume":"7","author":"SL Silverman","year":"2005","unstructured":"Silverman SL (2005) Quality-of-life issues in osteoporosis. Curr Rheumatol Rep 7:39\u201345","journal-title":"Curr Rheumatol Rep"},{"issue":"Suppl 1","key":"490_CR49","first-page":"128","volume":"13","author":"CH Chesnut","year":"2002","unstructured":"Chesnut CH, Richardson P, Mindeholm L (2002) Salmon calcitonin nasal spray (SCNS): effect on hip fractures in postmenopausal women [abstract]. Osteoporos Int 13(Suppl 1):128","journal-title":"Osteoporos Int"},{"key":"490_CR50","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1016\/S8756-3282(03)00241-2","volume":"33","author":"PD Delmas","year":"2003","unstructured":"Delmas PD, Genant HK, Crans GG, Stock JL, Wong M, Siris E, Adachi JD (2003) Severity of prevalent vertebral fractures and the risk of subsequent vertebral and nonvertebral fractures: results from the MORE trial. Bone 33:522\u2013532","journal-title":"Bone"},{"key":"490_CR51","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1359\/JBMR.040325","volume":"19","author":"C Chesnut","year":"2004","unstructured":"Chesnut C, Skag A, Christiansen C, Recker R, Stakkestad J, Hoiseth A, Felsenberg D, Huss H, Gilbride J, Schimmer R, Delmas P (2004) Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis. J Bone Miner Res 19:1241\u20131249","journal-title":"J Bone Miner Res"},{"key":"490_CR52","doi-asserted-by":"crossref","first-page":"2163","DOI":"10.1359\/jbmr.2001.16.12.2163","volume":"16","author":"CH Chesnut III","year":"2001","unstructured":"Chesnut CH III, Rosen CJ (2001) Perspective: Reconsidering the effects of antiresorptive therapies in reducing osteoporotic fracture. J Bone Miner Res 16:2163\u20132172","journal-title":"J Bone Miner Res"},{"key":"490_CR53","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1185\/030079903125003062","volume":"20","author":"C Cefalu","year":"2004","unstructured":"Cefalu C (2004) Is bone mineral density predictive of fracture risk reduction ? Curr Med Res Opin 20:341\u2013349","journal-title":"Curr Med Res Opin"},{"key":"490_CR54","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1359\/jbmr.2002.17.1.1","volume":"17","author":"S Sarkar","year":"2002","unstructured":"Sarkar S, Mitlak BH, Wong M, Stock JL, Black DM, Harper KD (2002) Relationships between bone mineral density and incident vertebral fracture risk with raloxifene therapy. J Bone Miner Res 17:1\u201310","journal-title":"J Bone Miner Res"},{"issue":"Suppl 1","key":"490_CR55","first-page":"S12","volume":"17","author":"M Olson","year":"2006","unstructured":"Olson M, Mindeholm L, Eriksen EF, Majumdar S, Azria M, Chesnut C (2006) Trabecular number as risk factor in osteoporosis and the role of nasal spray calcitonin (NS-CT) in its modification [abstract]. Osteoporos Int 17(Suppl 1):S12\u2013S13","journal-title":"Osteoporos Int"},{"key":"490_CR56","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1359\/JBMR.041008","volume":"20","author":"Y Jiang","year":"2005","unstructured":"Jiang Y, Zhao J, Geusens P, Liao EY, Adriaensens P, Gelan J, Azria M, Boonen S, Caulin F, Lynch JA, Ouyang X, Genant HK (2005) Femoral neck trabecular microstructure in ovariectomized ewes treated with calcitonin: MRI microscopic evaluation. J Bone Miner Res 20:125\u2013130","journal-title":"J Bone Miner Res"},{"key":"490_CR57","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1185\/030079904125003071","volume":"20","author":"E Lufkin","year":"2004","unstructured":"Lufkin E, Sarkar S, Kulkarni M, Ciaccia A, Siddhanti S, Stock J, Plouffe L (2004) Antiresorptive treatment of postmenopausal osteoporosis: review of randomized clinical studies and rationale for the Evista alendronate comparison (EVA) trial. Curr Med Res Opin 20:351\u2013357","journal-title":"Curr Med Res Opin"},{"key":"490_CR58","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1210\/edrv.23.1.0453","volume":"23","author":"R Marcus","year":"2002","unstructured":"Marcus R, Wong M, Heath H, Stock J (2002) Antiresorptive treatment of postmenopausal osteoporosis: comparison of study designs and outcomes in clinical trials with fracture as endpoint. Endocr Rev 23:16\u201337","journal-title":"Endocr Rev"},{"key":"490_CR59","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1007\/s00198-004-1812-1","volume":"16","author":"S Boonen","year":"2005","unstructured":"Boonen S, Body J, Boutsen Y, Devogelaer J, Goemaere S, Kaufman J, Rozenberg S, Reginster J (2005) Evidence-based guidelines for the treatment of postmenopausal osteoporosis: a consensus document of the Belgian Bone Club. Osteoporos Int 16:239\u2013254","journal-title":"Osteoporos Int"},{"key":"490_CR60","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1001\/jama.285.11.1415","volume":"285","author":"D Altkorn","year":"2001","unstructured":"Altkorn D, Vokes T (2001) Treatment of postmenopausal osteoporosis. JAMA 285:1415\u20131418","journal-title":"JAMA"},{"key":"490_CR61","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.1097\/01.smj.0000184921.53062.bf","volume":"98","author":"R Hamdy","year":"2005","unstructured":"Hamdy R, Chesnut CH 3rd, Holick M, Leib E, Lewiecki M, Maricic M, Watts N (2005) Review of treatment modalities for postmenopausal osteoporosis. South Med J 98:1000\u20131014","journal-title":"South Med J"},{"key":"490_CR62","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1016\/j.bone.2003.12.013","volume":"34","author":"B Borah","year":"2004","unstructured":"Borah B, Dufresne TE, Chmielewski PA, Johnson TD, Chines A, Manhart MD (2004) Risedronate preserves bone architecture in postmenopausal women with osteoporosis as measured by three-dimensional microcomputed tomography. Bone 34:736\u2013746","journal-title":"Bone"},{"key":"490_CR63","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1359\/jbmr.2002.17.3.521","volume":"17","author":"GP Trovas","year":"2002","unstructured":"Trovas GP, Lyritis GP, Galanos A, Raptou P, Constantelou E (2002) A randomized trial of nasal spray salmon calcitonin in men with idiopathic osteoporosis: effects on bone mineral density and bone markers. J Bone Miner Res 17:521\u2013527","journal-title":"J Bone Miner Res"},{"key":"490_CR64","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.bone.2004.09.003","volume":"36","author":"E Toth","year":"2005","unstructured":"Toth E, Csupor E, Meszaros S, Ferencz V, Nemeth L, McCloskey EV, Horvath C (2005) The effect of intranasal salmon calcitonin therapy on bone mineral density in idiopathic male osteoporosis without vertebral fractures-an open label study. Bone 36:47\u201351","journal-title":"Bone"},{"key":"490_CR65","first-page":"205","volume":"11","author":"KK Pun","year":"1989","unstructured":"Pun KK, Chan LW (1989) Analgesic effect of intranasal salmon calcitonin in the treatment of osteoporotic vertebral fractures. Clin Ther 11:205\u2013209","journal-title":"Clin Ther"},{"key":"490_CR66","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1080\/17453674.1997.11744761","volume":"275","author":"GP Lyritis","year":"1997","unstructured":"Lyritis GP, Paspati I, Karachalios T, Ioakimidis D, Skarantavos G, Lyritis PG (1997) Pain relief from nasal salmon calcitonin in osteoporotic vertebral crush fractures. A double blind, placebo-controlled clinical study. Acta Orthop Scand Suppl 275:112\u2013114","journal-title":"Acta Orthop Scand Suppl"},{"key":"490_CR67","first-page":"CD001983","volume":"2","author":"A Cranney","year":"2000","unstructured":"Cranney A, Welch V, Adachi JD, Homik J, Shea B, Suarez-Almazor ME, Tugwell P, Wells G (2000) Calcitonin for the treatment and prevention of corticosteroid-induced osteoporosis. Cochrane Database Syst Rev 2:CD001983","journal-title":"Cochrane Database Syst Rev"},{"key":"490_CR68","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1210\/jcem-31-3-283","volume":"31","author":"NH Bell","year":"1970","unstructured":"Bell NH, Avery S, Johnston CC (1970) Effects of calcitonin in Paget\u2019s disease and polyostotic fibrous dysplasia. J Clin Endocrinol 31:283\u2013290","journal-title":"J Clin Endocrinol"},{"key":"490_CR69","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1001\/jama.1972.03200230015004","volume":"221","author":"EB Goldfield","year":"1972","unstructured":"Goldfield EB, Braiker BM, Prendergast JJ, Kolb FO (1972) Synthetic salmon calcitonin: treatment of Paget\u2019s disease and osteogenesis imperfecta. JAMA 221:1127\u20131129","journal-title":"JAMA"},{"key":"490_CR70","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1136\/bmj.3.5933.727","volume":"3","author":"JA Kanis","year":"1974","unstructured":"Kanis JA, Horn DB, Scott RDM, Strong JA (1974) Treatment of Paget\u2019s disease of bone with synthetic salmon calcitonin. BMJ 3:727\u2013731","journal-title":"BMJ"},{"key":"490_CR71","first-page":"712","volume":"44","author":"C Gennari","year":"1988","unstructured":"Gennari C, Agnusdei D (1988) Calcitonin in bone pain management. Curr Ther Res 44:712\u2013722","journal-title":"Curr Ther Res"},{"key":"490_CR72","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/8756-3282(88)90028-2","volume":"9","author":"H Rico","year":"1988","unstructured":"Rico H, Hernandez ER, Younes M, Hernandez D, Espinos D (1988) Biochemical assessment of actue and chronic treatment of Paget\u2019s bone disease with calcitonin and calcium with and without bisphosphonate. Bone 9:63\u201366","journal-title":"Bone"},{"key":"490_CR73","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1259\/0007-1285-50-598-699","volume":"50","author":"NJY Woodhouse","year":"1977","unstructured":"Woodhouse NJY, Chalmers AH, Wells IP, Dewbury KC, Mohamedally SM (1977) Paget\u2019s disease. Radiological changes occuring in untreated patients and those on therapy with salmon calcitonin during two years\u2019 observation. Br J Radiol 50:699\u2013705","journal-title":"Br J Radiol"},{"key":"490_CR74","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1007\/BF02064100","volume":"22","author":"GR Delling","year":"1977","unstructured":"Delling GR, Schultz A, Siegler R (1977) Changes of bone remodelling surfaces and bone structure in Paget\u2019s disease following long-term treatment with calcitonin. Calcif Tissue Res 22:359\u2013361","journal-title":"Calcif Tissue Res"},{"key":"490_CR75","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1016\/S0046-8177(78)80030-6","volume":"9","author":"VL Fornasier","year":"1978","unstructured":"Fornasier VL, Stapleton K, Williams CC (1978) Histologic changes in Paget\u2019s disease treated with calcitonin. Human Path 9:455\u2013461","journal-title":"Human Path"},{"key":"490_CR76","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1136\/bmj.1.6057.357","volume":"1","author":"GA Evans","year":"1977","unstructured":"Evans GA, Slee GC (1977) Calcitonin for multiple fractures in Paget\u2019s disease. Br Med J 1:357","journal-title":"Br Med J"},{"issue":"Suppl 2","key":"490_CR77","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1002\/jbmr.5650140211","volume":"14","author":"E Siris","year":"1999","unstructured":"Siris E (1999) Goals of treatment for Paget\u2019s disease of bone. J Bone Miner Res 14(Suppl 2):49\u201352","journal-title":"J Bone Miner Res"},{"key":"490_CR78","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1007\/BF02935550","volume":"5","author":"PM Sexton","year":"1992","unstructured":"Sexton PM (1992) Central nervous system binding sites for calcitonin and calcitonin gene-related peptide. Mol Neurobiol 5:251\u2013273","journal-title":"Mol Neurobiol"},{"key":"490_CR79","doi-asserted-by":"crossref","first-page":"7801","DOI":"10.1073\/pnas.78.12.7801","volume":"78","author":"JA Fischer","year":"1981","unstructured":"Fischer JA, Tobler PH, Kaufmann M, Born W, Henke H, Cooper PE, Sagar SM, Martin JB (1981) Calcitonin: regional distribution of the hormone and its binding sites in the human brain and pituitary. Proc Natl Acad Sci 78:7801\u20137805","journal-title":"Proc Natl Acad Sci"},{"key":"490_CR80","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1055\/s-2007-1012291","volume":"18","author":"L Laurian","year":"1986","unstructured":"Laurian L, Oberman Z, Graff E, Gilard S, Hoerer E, Simantov R (1986) Calcitonin-induced increase in ACTH, \u03b2-endorphin and cortisol secretion. Hormone Metab Res 18:268\u2013271","journal-title":"Hormone Metab Res"},{"key":"490_CR81","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/0014-2999(94)90175-9","volume":"252","author":"M Colado","year":"1994","unstructured":"Colado M, Ormazabal M, Goicoechea C, Lopez F, Alfaro M, Martin M (1994) Involvement of central serotonergic pathways in analgesia elicited by salmon calcitonin in the mouse. Eur J Pharmacol 252:291\u2013297","journal-title":"Eur J Pharmacol"},{"key":"490_CR82","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1016\/0014-2999(84)90298-X","volume":"98","author":"G Clementi","year":"1984","unstructured":"Clementi G, Prato A, Conforto G, Scapagnini U (1984) Role of serotonin in the analgesic activity of calcitonin. Eur J Pharmacol 98:449\u2013451","journal-title":"Eur J Pharmacol"},{"key":"490_CR83","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1007\/s001980200118","volume":"13","author":"SL Silverman","year":"2002","unstructured":"Silverman SL, Azria M (2002) The analgesic role of calcitonin following osteoporotic fracture. Osteoporos Int 13:858\u2013867","journal-title":"Osteoporos Int"},{"key":"490_CR84","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1007\/BF02555844","volume":"49","author":"GP Lyritis","year":"1991","unstructured":"Lyritis GP, Tsakalakos N, Magiasis B, Karachalios T, Yiatzides, Tsekoura M (1991) Analgesic effect of salmon calcitonin in osteoporotic vertebral fractures: A double-blind placebo-controlled clinical study. Calcif Tissue Int 49:369\u2013372","journal-title":"Calcif Tissue Int"},{"key":"490_CR85","first-page":"298","volume":"38","author":"C Gennari","year":"1985","unstructured":"Gennari C, Chierichetti SM, Piolini M, Vibelli C, Agnusdei D, Civitelli R, Gonelli S (1985) Analgesic activity of salmon and human calcitonin against cancer pain: a double-blind, placebo-controlled clinical study. Curr Ther Res 38:298\u2013308","journal-title":"Curr Ther Res"},{"key":"490_CR86","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1634\/theoncologist.9-5-571","volume":"9","author":"D Lussier","year":"2004","unstructured":"Lussier D, Huskey AG, Portenoy RK (2004) Adjuvant analgesics in cancer pain management. Oncologist 9:571\u2013591","journal-title":"Oncologist"},{"key":"490_CR87","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1016\/S0885-3924(01)00282-2","volume":"21","author":"RS Perez","year":"2001","unstructured":"Perez RS, Kwakkel G, Zuurmond WW, de Lange JJ (2001) Treatment of reflex sympathetic dystrophy (CRPS type 1): a research synthesis of 21 randomized clinical trials. J Pain Symptom Manage 21:511\u2013526","journal-title":"J Pain Symptom Manage"},{"key":"490_CR88","doi-asserted-by":"crossref","first-page":"278","DOI":"10.5694\/j.1326-5377.1981.tb128316.x","volume":"2","author":"HS Grunstein","year":"1981","unstructured":"Grunstein HS, Clifton-Bligh P, Posen S (1981) Paget\u2019s disease of bone: experiences with 100 patients treated with salmon calcitonin. Med J Aus 2:278\u2013280","journal-title":"Med J Aus"},{"key":"490_CR89","doi-asserted-by":"crossref","first-page":"1620","DOI":"10.1055\/s-2008-1070566","volume":"106","author":"F Kuhlencordt","year":"1981","unstructured":"Kuhlencordt F, Ringe JD, Kruse HP (1981) Behandlung der Osteodystrophia deformans Paget mit Lachs-Calcitonin. Dtsch Med Wochenschr 106:1620\u20131623","journal-title":"Dtsch Med Wochenschr"},{"key":"490_CR90","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1007\/s00774-004-0591-2","volume":"23","author":"P Peichl","year":"2005","unstructured":"Peichl P, Marteau R, Griesmacher A, Kumpan W, Schedl R, Prosquil E, Fasol P, Broll H (2005) Salmon calcitonin nasal spray treatment for postmenopausal women after hip fracture with total hip arthroplasty. J Bone Miner Metab 23:243\u2013252","journal-title":"J Bone Miner Metab"},{"key":"490_CR91","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1007\/s00223-001-2111-x","volume":"71","author":"TM Huusko","year":"2002","unstructured":"Huusko TM, Karppi P, Kautiainen H, Suominen H, Avikainen V, Sulkava R (2002) Randomized, double-blind, clinically controlled trial of intranasal calcitonin treatment in patients with hip fracture. Calcif Tissue Int 71:478\u2013484","journal-title":"Calcif Tissue Int"},{"key":"490_CR92","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1007\/s002239900284","volume":"61","author":"B Combe","year":"1997","unstructured":"Combe B, Cohen C, Aubin F (1997) Equivalence of nasal spray and subcutaneous formulations of salmon calcitonin. Calcif Tissue Int 61:10\u201315","journal-title":"Calcif Tissue Int"},{"key":"490_CR93","first-page":"2160","volume":"44","author":"WP Maksymowych","year":"1998","unstructured":"Maksymowych WP (1998) Managing acute osteoporotic vertebral fractures with calcitonin. Can Fam Physician 44:2160\u20132166","journal-title":"Can Fam Physician"},{"key":"490_CR94","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1345\/aph.1C350","volume":"37","author":"LA Blau","year":"2003","unstructured":"Blau LA, Hoehns JD (2003) Analgesic efficacy of calcitonin for vertebral fracture pain. Ann Pharmacother 37:564\u2013570","journal-title":"Ann Pharmacother"},{"key":"490_CR95","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1007\/s00198-004-1798-8","volume":"16","author":"JA Knopp","year":"2005","unstructured":"Knopp JA, Diner BM, Blitz M, Lyritis GP, Rowe BH (2005) Calcitonin for treating acute pain of osteoporotic vertebral compression fractures: a systematic review of randomized, controlled trials. Osteoporosis Int 16:1281\u20131290","journal-title":"Osteoporosis Int"},{"issue":"11","key":"490_CR96","first-page":"1039","volume":"115","author":"R Arinoviche","year":"1987","unstructured":"Arinoviche R, Arriagada M, Jacobelli S, Massardo L, Rivero S, Aris H, Valenzuela M, Rojas C, Carvallo A, Gatica H et al (1987) [Calcitonin in acute pain due to vertebral fracture in osteoporosis. Cooperative study] Rev Med Chil 115(11):1039\u20131043","journal-title":"Rev Med Chil"},{"key":"490_CR97","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1097\/00002508-199912000-00004","volume":"15","author":"GP Lyritis","year":"1999","unstructured":"Lyritis GP, Ioannidis GV, Karachalios T, Roidis N, Kataxaki E, Papaioannou N, Kaloudis J, Galanos A (1999) Analgesic effect of salmon calcitonin suppositories in patients with acute pain due to recent osteoporotic vertebral crush fractures: a prospective double-blind, randomized, placebo-controlled clinical study. Clin J Pain 15:284\u2013289","journal-title":"Clin J Pain"},{"key":"490_CR98","doi-asserted-by":"crossref","first-page":"378","DOI":"10.2165\/00002512-199608050-00006","volume":"8","author":"GL Plosker","year":"1991","unstructured":"Plosker GL, McTavish D (1991) Intranasal salcatonin (salmon calcitonin): a review of its pharmacological properties and role in the management of postmenopausal osteoporosis. Drugs Aging 8:378\u2013400","journal-title":"Drugs Aging"},{"key":"490_CR99","doi-asserted-by":"crossref","first-page":"405","DOI":"10.2165\/00002512-199101050-00007","volume":"1","author":"S Clissold","year":"1991","unstructured":"Clissold S, Fitton A, Chrisp P (1991) Intranasal salmon calcitonin. A review of its pharmacological properties and potential utility in metabolic bone disorders associated with aging. Drugs Aging 1:405\u2013423","journal-title":"Drugs Aging"},{"key":"490_CR100","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1016\/0011-393X(95)85012-0","volume":"56","author":"R Foti","year":"1995","unstructured":"Foti R, Martorana U, Broggini M (1995) Long-term tolerability of nasal spray formulation of salmon calcitonin. Curr Ther Res 56:429\u2013435","journal-title":"Curr Ther Res"},{"key":"490_CR101","doi-asserted-by":"crossref","first-page":"1478","DOI":"10.1359\/jbmr.2002.17.8.1478","volume":"17","author":"T Buclin","year":"2002","unstructured":"Buclin T, Cosma Rochat M, Burckhardt P, Azria M, Attinger M (2002) Bioavailability and biological efficacy of a new oral formulation of salmon calcitonin in healthy volunteers. J Bone Miner Res 17:1478\u20131485","journal-title":"J Bone Miner Res"},{"key":"490_CR102","doi-asserted-by":"crossref","first-page":"1531","DOI":"10.1359\/JBMR.040715","volume":"19","author":"LB Tanko","year":"2004","unstructured":"Tanko LB, Bagger YZ, Alesandersen P, Devogelaer JP, Reginster JY, Chick R, Olson M, Benmammar H, Mindeholm L, Azria M, Christiansen C (2004) Safety and efficacy of a novel salmon calcitonin (sCT) technology-based oral formulation in healthy postmenopausal women: acute and 3-month effects on biomarkers of bone turnover. J Bone Miner Res 19:1531\u20131538","journal-title":"J Bone Miner Res"},{"key":"490_CR103","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1016\/j.bone.2005.04.032","volume":"37","author":"YZ Bagger","year":"2005","unstructured":"Bagger YZ, Tanko LB, Alexandersen P, Karsdal MA, Olson M, Mindeholm L, Azria M, Christiansen C (2005) Oral salmon calcitonin induced suppression of urinary collagen type II degradation in postmenopausal women: a new potential treatment of osteoarthritis. Bone 37:425\u2013430","journal-title":"Bone"},{"key":"490_CR104","first-page":"285","volume":"5","author":"DH Manicourt","year":"2005","unstructured":"Manicourt DH, Devogelaer JP, Azria M, Silverman S (2005) Rationale for the potential use of calcitonin in osteoarthritis. J Musculoskelet Neuronal Interact 5:285\u2013293","journal-title":"J Musculoskelet Neuronal Interact"},{"key":"490_CR105","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1002\/1529-0131(199906)42:6<1159::AID-ANR12>3.0.CO;2-Q","volume":"42","author":"DH Manicourt","year":"1999","unstructured":"Manicourt DH, Altman RD, Williams JM, Devogelaer JP, Druetz-Van Egeren A, Lenz ME, Pietryla D, Thonar EJ (1999) Treatment with calcitonin suppresses the responses of bone, cartilage, and synovium in the early stages of canine experimental osteoarthritis and significantly reduces the severity of the cartilage lesions. Arthritis Rheum 42:1159\u20131167","journal-title":"Arthritis Rheum"},{"key":"490_CR106","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1016\/j.joca.2006.03.014","volume":"14","author":"MA Karsdal","year":"2006","unstructured":"Karsdal MA, Tanko LB, Riis BJ, Sondergard BC, Henriksen K, Altman RD, Qvist P, Christiansen C (2006) Calcitonin is involved in cartilage homeostasis: Is calcitonin a treatment for OA ? Osteoarth Cartil 14:617\u2013624","journal-title":"Osteoarth Cartil"},{"key":"490_CR107","first-page":"1533","volume":"348","author":"D Black","year":"1996","unstructured":"Black D, Cummings S, Karpf D, Cauley J, Thompson D, Nevitt M, Bauer D, Genant H, Haskell W, Marcus R, Ott S, Torner J, Quandt S, Reiss T, Ensrud K (1996) Randomized trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group. Lancet 348:1533\u20131541","journal-title":"Lancet"},{"key":"490_CR108","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1001\/jama.282.7.637","volume":"282","author":"B Ettinger","year":"1999","unstructured":"Ettinger B, Black D, Mitlak B, Knickerbocker R, Nickelson T, Genant H, Christiansen C, Delmas P, Zanchetta J, Stakkestad J, Gluer C, Krueger K, Cohen F, Eckert S, Alvioloi L, Lips P, Cummings S (1999) Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators. JAMA 282: 637\u2013645","journal-title":"JAMA"},{"key":"490_CR109","doi-asserted-by":"crossref","first-page":"1140","DOI":"10.1001\/archinte.162.10.1140","volume":"162","author":"M Maricic","year":"2002","unstructured":"Maricic M, Adachi JD, Sarkar S, Wu W, Wong M, Harper KD (2002) Early effects of raloxifene on clinical vertebral fractures at 12\u00a0months in postmenopausal women with osteoporosis. Arch Intern Med 162:1140\u20131143","journal-title":"Arch Intern Med"},{"key":"490_CR110","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1001\/jama.282.14.1344","volume":"282","author":"S Harris","year":"1999","unstructured":"Harris S, Watts N, Genant H, McKeever C, Hantgartner T, Keller, M, Chesnut C, Brown J, Eriksen E, Hoseyni M, Axelrod D, Miller P (1999) Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy with Risedronate Therapy (VERT) Study Group. JAMA 282:1344\u20131352","journal-title":"JAMA"},{"key":"490_CR111","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1007\/s001980050010","volume":"11","author":"JY Reginster","year":"2000","unstructured":"Reginster JY, Minne H, Sorenson O, Hooper M, Roux C, Brandi M, Lund B, Ethgen D, Pack S, Roumagnac I, Eastell R (2000) Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Vertebral Efficacy with Risedronate Therapy (VERT) Study Group. Osteoporos Int 11:83\u201391","journal-title":"Osteoporos Int"},{"key":"490_CR112","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1056\/NEJMoa022436","volume":"350","author":"P Meunier","year":"2004","unstructured":"Meunier P, Roux C, Seeman E, Ortolanis, Badurski J, Spector T, Cannata J, Balogh A, Lemmel E, Pors-Nielsen S, Rizzoli R, Genant H, Reginster J (2004) The effects of strontium ranelate on the risk of vertebral fracture in women with postmenopausal osteoporosis. N Engl J Med 350:459\u2013468","journal-title":"N Engl J Med"},{"key":"490_CR113","unstructured":"EMEA: Scientific discussion \n                    http:\/\/www.emea.eu.int\/humandocs\/PDFs\/EPAR\/protelos\/121604en6.pdf"}],"container-title":["Osteoporosis International"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00198-007-0490-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00198-007-0490-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00198-007-0490-1","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00198-007-0490-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,2,17]],"date-time":"2020-02-17T16:55:10Z","timestamp":1581958510000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00198-007-0490-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,12,11]]},"references-count":113,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2008,4]]}},"alternative-id":["490"],"URL":"https:\/\/doi.org\/10.1007\/s00198-007-0490-1","relation":{},"ISSN":["0937-941X","1433-2965"],"issn-type":[{"value":"0937-941X","type":"print"},{"value":"1433-2965","type":"electronic"}],"subject":[],"published":{"date-parts":[[2007,12,11]]}}}